Major depressive disorder is a complex mental health condition characterized by pervasive mood disturbances and cognitive deficits. ReHo, which evaluates the consistency of neural activity within adjacent brain regions, has emerged as a sensitive biomarker to probe the dysregulation inherent in MDD. Until now, the subtle interplay between age-related neural variations and depressive pathology remained elusive. This study pioneers the exploration of how ReHo differs across age groups in individuals experiencing their first episode of major depression.

The investigators stratified patients into three distinct age cohorts—young adults (16–24 years), middle-aged adults (25–39 years), and older adults within middle age (40–54 years)—to dissect the nuanced age-dependent modifications in neural coherence. The research leveraged one of the most extensive neuroimaging datasets available, enhancing statistical power and ensuring replicability of findings. This stratification revealed strikingly different topographies of ReHo alterations contingent on age, highlighting the dynamic nature of depression’s neural footprint.

In young patients, the study found pronounced decreases in ReHo within the right middle frontal gyrus, right superior parietal lobule, and left inferior temporal gyrus. These regions are integral to cognitive control, attentional processes, and emotion regulation. The impaired synchronization in these clusters suggests early disruptions in executive functioning networks and sensory integration processes, potentially underpinning the clinical symptomatology observed in adolescent and young adult depression.

For the adult subgroup, ReHo deficits manifested primarily in frontal regions, including the right superior frontal gyrus, left middle frontal gyrus, and right inferior frontal gyrus. This frontal lobe attenuation aligns with the established role of prefrontal cortical areas in mood regulation, decision-making, and higher-order cognitive functions typically compromised in depression. The lateralized pattern points to possible hemispheric distinctions in the pathophysiology of adult-onset major depressive disorder.

Middle-aged individuals exhibited a different constellation of ReHo abnormalities, with reductions localized to the right paracentral lobule, right inferior temporal gyrus, and left middle occipital gyrus. These cerebral zones are implicated in sensorimotor integration, visual processing, and memory. The involvement of such diverse regions may reflect the compound effects of aging and chronic stress-related neural remodeling characteristic of later-life depression.

Beyond discrete regional changes, the study identified a progressive age-related decline in ReHo in key cortical areas, specifically the left postcentral gyrus, left superior parietal lobule, and left superior temporal gyrus. These findings highlight a trajectory of diminishing local neural coherence that correlates with both chronological aging and depressive pathology. Such gradients of neural diminishing emphasize the importance of age as a modulatory factor in the neurobiological underpinnings of MDD.

A particularly noteworthy discovery was the significant disease effect observed in the right superior frontal gyrus across all age groups, reinforcing this region’s pivotal role in the neuropathology of depression. Moreover, the data revealed an interaction between age and disease status in the right superior occipital gyrus, suggesting that visual and associative processing hubs may be differentially affected depending on the age at depression onset.

To assess the translational applicability of their findings, the researchers conducted receiver operating characteristic (ROC) analyses to evaluate the diagnostic potential of age-specific ReHo patterns. The outcomes were promising, indicating strong discriminative power particularly within the adult and middle-aged populations. This approach underscores ReHo’s emerging utility as a biomarker for early diagnosis and personalized treatment stratification in MDD.

The implications of this research extend beyond diagnostics. By delineating the age-dependent neural signatures of depression, it fosters a more nuanced understanding of the disorder’s heterogeneity, potentially guiding the development of age-tailored therapeutic interventions. The clear differentiation of affected brain regions across lifespan stages advocates for precision medicine approaches that account for neurodevelopmental and neurodegenerative changes.

This study teams rigorous methodological design with cutting-edge neuroimaging, embodying a paradigm shift in psychiatric research towards integrating neurobiological metrics with clinical phenotyping. Its findings beckon further exploration into the causal mechanisms linking ReHo alterations to symptom dimensions and treatment outcomes, potentially bridging the gap between neuroscience and clinical psychiatry.

As mental health practitioners grapple with the societal burden of MDD, insights from this investigation offer hope for improving prognostic accuracy and therapeutic efficacy. Future research trajectories might explore longitudinal changes in ReHo post-treatment and examine how environmental and genetic moderators interface with these neural biomarkers.

In sum, the elucidation of age-specific ReHo changes in first-episode major depressive disorder charts a new frontier in understanding the brain’s dynamic response to depression. It establishes a compelling neurophysiological narrative that intersects developmental neurobiology and psychopathology, promising to reshape diagnostic frameworks and personalized care models in depression.

Subject of Research: Alterations in regional brain homogeneity (ReHo) related to age in first-episode major depressive disorder patients.

Article Title: Age-related regional homogeneity changes in first-episode major depressive disorder: a REST-meta-MDD project study

Article References:
Liu, Z., Wu, H., Xu, Y. et al. Age-related regional homogeneity changes in first-episode major depressive disorder: a REST-meta-MDD project study. BMC Psychiatry 25, 1049 (2025). https://doi.org/10.1186/s12888-025-07406-x

Image Credits: AI Generated

DOI: 03 November 2025

Keywords: Major depressive disorder, regional homogeneity, ReHo, neuroimaging, age-related brain changes, first-episode depression, neural synchronization, REST-meta-MDD, biomarkers, diagnostic imaging

Major depressive disorder remains a global health challenge, frequently presenting alongside anxiety symptoms that exacerbate patient suffering and complicate treatment responses. While prior clinical observations have noted behavioral discrepancies between anxious and nonanxious MDD patients, the neurobiological substrates underlying these differences have remained enigmatic. By focusing exclusively on first-episode, drug-naïve patients, this study minimizes confounding effects related to medication and disease chronicity, lending robustness to its findings and potentially illuminating early pathological changes predating therapeutic intervention.

The researchers harnessed resting-state fMRI to measure regional homogeneity (ReHo)—a metric reflecting local synchronization of neuronal activity—providing a window into the intrinsic functional architecture of the brain. Subjects included 42 anxious MDD patients, 42 nonanxious MDD patients, and 45 healthy controls. Controlling for gray matter volume ensured that observed differences in ReHo values could be attributed to functional abnormalities rather than structural brain changes. This comprehensive approach allowed for nuanced comparisons aimed at identifying both shared and unique disruptions in brain activity.

Results revealed a striking convergence and divergence in regional brain dysfunctions between the two MDD subgroups. Both anxious and nonanxious patients exhibited decreased ReHo in several key brain areas, including the inferior temporal gyrus, precuneus, supplementary motor area, and putamen, underscoring a possible common neural signature of MDD. These regions are associated with cognitive processing, self-referential thinking, motor planning, and reward—functions often disrupted in depressive states. The observed hypoactivity suggests diminished spontaneous neuronal synchronization, which could underlie characteristic symptoms such as cognitive slowing and impaired motivation.

However, the distinction emerged with the nonanxious MDD group demonstrating additional reduced ReHo in the middle frontal gyrus, a region integral to executive function and emotion regulation. This unique alteration may hint at differential impairments in top-down cognitive control mechanisms, potentially accounting for variations in symptom profiles and treatment responsiveness. The supplementary motor area, inversely correlated with depression severity scores, highlights its role as a neural marker reflective of clinical state intensity.

Perhaps most notably, decreased ReHo in the right parahippocampal gyrus was found exclusively in anxious MDD patients when contrasted against their nonanxious counterparts. The parahippocampal region, intimately involved in memory encoding and emotional processing, has long been implicated in anxiety disorders. This selective hypoactivity could signify a neural correlate of heightened anxiety symptoms within depressive pathology, offering a promising target for diagnostic and therapeutic exploration.

To assess the diagnostic utility of these neuroimaging findings, the team employed receiver operating characteristic (ROC) curve analysis, demonstrating that altered activity in the right parahippocampal gyrus could effectively distinguish anxious from nonanxious depression. This represents a vital step toward the realization of objective biomarkers in psychiatry, which to date has largely relied on subjective clinical assessments. Such biomarkers could enable early identification, personalized treatment approaches, and more precise monitoring of therapeutic outcomes.

From a mechanistic perspective, the broader depression-related decreases in spontaneous brain activity found in this study reinforce existing evidence of disrupted intrinsic brain networks in MDD. The amplified regional hypoactivity in anxious patients suggests that comorbidity may reflect an additive or synergistic neural pathology rather than merely overlapping symptomatology. This distinction is critical as it advocates for tailored interventions addressing both depressive and anxious components simultaneously.

The implications of these findings extend beyond academic curiosity, offering practical insights that clinicians and researchers alike can employ. Better understanding the neurophysiological divergence between anxious and nonanxious MDD informs prognosis and therapeutic direction. It may guide clinicians to consider adjunct treatments targeting anxiety circuits in depression or to refine psychotherapeutic strategies based on differential brain activity profiles.

Moreover, this research exemplifies the power of advanced neuroimaging combined with stringent patient selection criteria, illuminating pathways toward more precise psychiatric diagnostics that transcend the limitations of symptom-based classification. Identifying reliable neurobiological markers is a critical milestone in achieving the holy grail of psychiatry: personalized medicine grounded in objective measurement rather than trial-and-error prescribing.

Future investigations are warranted to replicate these findings in larger cohorts and explore longitudinal changes across treatment courses. Integrating multimodal imaging techniques, genetic profiling, and electrophysiological measures will enrich our understanding of the complex brain-behavior relationships in depressive disorders with anxiety. These multifaceted approaches promise to unravel the dynamic interplay of neurocircuitry that underpins symptom heterogeneity, ultimately enhancing patient outcomes.

In conclusion, the study unravels critical differences in spontaneous brain activity between first-episode drug-naïve anxious and nonanxious MDD patients, highlighting the right parahippocampal gyrus as a potential neuroimaging biomarker for anxiety comorbidity in depression. By delineating both shared and unique regional dysfunctions, the research offers a refined neurobiological framework for understanding and managing major depressive disorder’s multifaceted clinical spectrum. This innovation marks a significant stride toward precision psychiatry, where neuroimaging can guide diagnosis and tailor interventions in what has traditionally been a challenging mental health landscape.

Subject of Research: Investigation of regional brain activity differences in first-episode drug-naïve anxious versus nonanxious major depressive disorder patients.

Article Title: Similarities and differences of regional brain activity between first-episode drug-naïve anxious and nonanxious MDD patients.

Article References:
Liu, G., Sun, Z., Zhou, C. et al. Similarities and differences of regional brain activity between first-episode drug-naïve anxious and nonanxious MDD patients. BMC Psychiatry 25, 1034 (2025). https://doi.org/10.1186/s12888-025-07513-9

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07513-9

Major depressive disorder is a pervasive and debilitating mental health condition characterized by persistent low mood and a constellation of cognitive impairments that impair daily functioning and social integration. These cognitive impairments often linger even after mood symptoms improve, posing a significant challenge for clinicians. Traditionally, cognitive evaluations rely on extensive neuropsychological testing batteries, which are time-intensive and susceptible to subjective bias. The present study pioneers the use of RMT—a quantitative measure of motor cortical excitability obtained via transcranial magnetic stimulation (TMS)—as an objective, potentially scalable tool to predict cognitive function.

The investigation enrolled a sizable cohort of 158 first-episode, drug-naive patients with MDD, assessed between August 2023 and April 2024. The participants underwent the MATRICS Consensus Cognitive Battery (MCCB), a comprehensive suite designed to evaluate multiple cognitive domains relevant to psychiatric conditions, alongside RMT measurement via TMS. Additionally, hormone assays were performed to control for the modulatory effects of endocrine factors on neurocognitive function. This robust methodological framework ensured that the findings reflect intrinsic brain physiology rather than medication effects or hormonal confounds.

The analysis included 138 patients who completed all assessments, comprising 41 males and 97 females with an average age of approximately 19 years, marking a young cohort at a critical developmental period. Statistical correlations revealed that in the total sample, higher right hemisphere RMT correlated positively with enhanced attention and vigilance, as measured by the Continuous Performance Test-Identical Pairs (CPT-IP). This suggests that greater motor cortex excitability in the right hemisphere might confer an advantage in sustaining attention among individuals with depression, a domain frequently impaired in MDD.

Intriguingly, when stratified by sex, the data exposed starkly divergent patterns. In male patients, a higher left hemisphere RMT was associated with poorer verbal learning performance, gauged by the Hopkins Verbal Learning Test-Revised (HVLT-R), while the right hemisphere RMT exhibited a protective effect, correlating positively with verbal learning outcomes. Such lateralized correlations intimate that hemispheric motor cortical excitability differentially influences cognitive faculties in males, potentially mediating the severity and profile of cognitive dysfunction in depression. Female patients, however, showed no significant association between RMT and the cognitive domains assessed, underscoring a critical sex-specific dissociation.

These results bear profound implications for the pathophysiology and treatment of MDD. RMT, as a non-invasive and reproducible neurophysiological index, may serve as a biomarker reflecting the integrity of cortical excitability and its modulation of cognitive processes. The distinct lateralization and sex-dependent associations revealed here emphasize the necessity of incorporating biological sex as a fundamental variable in both research paradigms and clinical protocols. This nuanced understanding could refine therapeutic approaches, particularly those employing repetitive transcranial magnetic stimulation (rTMS), which targets motor cortex excitability to alleviate both mood and cognitive symptoms in depression.

Notably, the study’s multiple regression analyses demonstrated that the relationships between RMT and cognitive outcomes were independent of confounders such as age, education level, and hormone concentrations. This underscores the direct relevance of motor cortical excitability to cognitive performance, rather than these associations being secondary to demographic or endocrine factors. Consequently, RMT may emerge as an objective biomarker that surpasses traditional cognitive testing in predictive power and clinical utility.

Despite its promising findings, this exploratory study invites caution and calls for replication and extension. The relatively young sample and the cross-sectional design limit the generalizability and causal inferences. Longitudinal research encompassing larger, more diverse populations is essential to validate the prognostic value of RMT and to elucidate the mechanistic pathways linking motor cortical excitability and cognitive function in depression across the lifespan.

Moreover, the absence of significant correlations in female patients raises complex questions about sex-specific neurobiological mechanisms in depression. Future investigations might explore hormonal fluctuations, neuroinflammatory profiles, or genetic modulators that differentially influence cortical excitability and cognitive networks in women. Such research could unravel tailored interventions optimized for sex-based neurocircuitry differences.

Importantly, the integration of RMT assessment into clinical practice could revolutionize the management of cognitive impairments in MDD. Non-invasive brain stimulation techniques, calibrated based on individual RMT profiles, hold the promise to modulate neural plasticity and restore cognitive functions impaired by depression. This personalized neurotherapeutic approach aligns with the broader precision psychiatry movement, aiming for interventions that address not only mood symptoms but also the often-neglected cognitive dimensions of mental illness.

In summary, this pioneering study leverages the intersection of neurophysiology and cognitive psychiatry to identify RMT as a potential objective marker for cognitive capacities in drug-naive individuals with major depressive disorder. The elucidation of sex-specific patterns enhances our understanding of depression’s heterogeneous neurobiology and advocates for sex-informed clinical strategies. As rTMS and related modalities gain traction, the use of RMT could inform both prognosis and individualized treatment planning, heralding a new era in the holistic care of patients battling depression.

Xu, L., He, J., Yang, L., and colleagues have set a compelling precedent for future research exploring the neurobiological determinants of cognitive dysfunction in MDD. Their work, published in BMC Psychiatry, not only advances scientific knowledge but also opens avenues for innovative clinical applications that may alleviate the cognitive burden borne by millions affected by this debilitating disorder.

Subject of Research: Utilization of resting motor threshold (RMT) as a neurophysiological predictor of cognitive function in drug-naive patients with major depressive disorder (MDD), with a focus on sex-specific differences.

Article Title: Utilizing resting motor threshold to predict cognitive function in drug-naive patients with major depressive disorder

Article References:
Xu, L., He, J., Yang, L. et al. Utilizing resting motor threshold to predict cognitive function in drug-naive patients with major depressive disorder. BMC Psychiatry 25, 1001 (2025). https://doi.org/10.1186/s12888-025-07393-z

DOI: https://doi.org/10.1186/s12888-025-07393-z